Chronic Pruritus
Conditions
Brief summary
A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments
Detailed description
The sensation of itch is transmitted to the brain through the nervous system Several chemicals are involved in transmitting this signal This trial of VPD 737 is intended to treat this condition by blocking one of the chemicals involved in the transmission of the itch signal This is an oral drug administered once daily It has been used in other trials and has shown to be safe at the doses used in this trial The trial will involve once daily pills for 6 weeks. Subject will be asked to fill out questionnaires both electronically and on paper during the study period Patients will also be monitored for safety and will have blood taken for testing and several points during the trial Overall participation will last about 12 weeks
Interventions
DRUGVPD-737
NK1 Receptor Antagonist
DRUGPlacebo
Sponsors
Vyne Therapeutics Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of chronic pruritus and unresponsive to current therapies
Exclusion criteria
* Have chronic liver or renal disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Analog Scale | 6 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Verbal Response Scale | 6 weeks |
Countries
United States
Outcome results
None listed